St. Jude Medical upgraded to Outperform from Neutral at Credit Suisse Credit Suisse upgraded St. Jude Medical citing increased confidence in Durata following the company's investor day. Price target lowered to $43 from $48.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
St. Jude Medical's 3-D vessel reconstruction system approved in Europe St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform.